Yesterday 12% Plunge, Today 9.8% Surge…What Happened to Samsung Electronics

Summary

Park Se-ik reviews the day's market news, focusing on a detailed biotech call by analyst Uhm Min-hyung who sees the KOSDAQ healthcare index at its best entry in years with eight specific catalysts and names Alteogen, Olix, and others as preferred picks. He also touches on HMM's strong profitability, record foreign tourist spending, a bullish semiconductor forecast, and Samsung Electronics' volatile moves on buyback news, while advising investors to lighten equity exposure during the summer ahead of the July FOMC.

• Bio analyst Uhm Min-hyung says KOSDAQ healthcare index is deeply oversold with 8 catalysts, making it the best buy opportunity in 4-5 years.
• Alteogen is the top pick thanks to a Halozyme patent win and back-to-back tech transfer deals with GSK and Biogen.
• Olix is rated second-best because its L'Oréal deal can self-fund R&D without further capital raises.
• DND Pharmatech's MASH drug beat Boehringer in fibrosis endpoints, creating high deal probability.
• Other preferred biotech names include Hanall, LegoChem Bio, and Peptron each with distinct clinical or deal catalysts.
• HMM's bulk shipping expansion lifted its OPM to 3rd globally, but no trade call is made.
• Semiconductor market is seen doubling to $1.51T on HBM demand, but it is presented as a headline without a direct recommendation.
• Park Se-ik advises trimming positions and raising cash in summer due to uncertainty around the July FOMC meeting.